Nov. 15 at 4:45 PM
$DARE
👎
Ovaprene enrollment is expected to finish in 2026, with means study readout anticipated in 2027.
👎
With only a few weeks left in the year, it will be difficult to judge from Q4 whether "Dare to Play" is a success.
👎
According to the company’s 10-Q, there is substantial doubt about its ability to continue as a going concern over the next 12 months.
👎
As of September 30, 2025, the company had
$23.1 million in cash and cash equivalents and working capital of about
$3.8 million. Most of the unrestricted cash comes from grant funds, which can only be used for the specific direct costs related to the funded projects.
👎
There is currently no ATM (due to baby shelf) in place, so the company may need to pursue a more traditional type of financing.
